Advanced Pancreatic Cancer Clinical Trial
Official title:
A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are: - Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer. - Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer. Participants will be asked to complete the study procedures: - Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B. - Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. - Complete the study procedures specified in the protocol, which is guided by researchers.
Status | Recruiting |
Enrollment | 82 |
Est. completion date | December 29, 2026 |
Est. primary completion date | December 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Male and female aged 18-75 years old. The subjects must have informed consent to the study, and signed the written informed consent voluntarily. - Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology. - Measurable disease as defined by RECIST 1.1. - Without systemic treatment for pancreatic cancer. - ECOG physical strength score 0-2 - Estimated survival time >=3 months. - The adequate bone marrow fuction and coagulation function Exclusion Criteria: - Known allergy or hypersensitivity to any components of the investigational drug product. - Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R). - With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation. - With a history of other malignancies within 5 years. - During the trial, other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for local symptomatic radiotherapy) or traditional Chinese medicine must be used for anti-tumor treatment. - With conditions that significantly affected the absorption of oral drug. - Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds. - During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment. - Concomitant use of strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 14 days prior to randomization. - Previous peripheral neuropathy > grade 1 (Common Terminology Criteria for Adverse Events, version 5.0). - Diagnosed with immune deficiency or interstitial lung disease. - The patients were vaccinated within 4 weeks before the first treatment. - Participated in any drug clinical trial within 4 weeks before the first treatment. - Active central nervous system (CNS) metastases. - Impaired cardiac function or clinically significant cardiac disease. - Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study. - Known active infections from certain viruses, bacteria or parasites. - Patients with refractory/uncontrolled ascites or pleural effusion. - Pregnant or lactating women. - Any other clinically significant comorbidities, which in the judgment of the Investigator, should not be included. |
Country | Name | City | State |
---|---|---|---|
China | West China Hospital of Sichuan University | Chengdu | |
China | Harbin Medical University Cancer Hospital | Ha'erbin | |
China | Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine | Shanghai | Shanghai |
China | Shanghai East Hospital Tongji University | Shanghai | |
China | Union Hospital Tongji Medical College Huazhong University of science and technolog | Wuhan |
Lead Sponsor | Collaborator |
---|---|
Abbisko Therapeutics Co, Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety Event Occurance | The Number of Participants With Adverse Event (AE), a Serious Adverse Event (SAE) and Dose Limiting Toxicities (DLT) Event. | From the day signed informed consent form to day 90 after the end of cycle 8 (each cycle is 21 days) | |
Primary | Objective Response Rate (ORR) | The Percentage of Participants with confirmed Complete Response and Partial Response, in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1) | From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days) | |
Secondary | Duration of Response | Duration of response (DOR) is defined as the time from the date of the first documentation of confirmed response (Complete Response or Partial Response) to the first objective documentation of progressive disease (PD) per RECIST v1.1 per Investigator assessment, or to death due to any cause in the absence of documented PD. | From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days) | |
Secondary | Progression Free Survival | Progression-free survival (PFS) was defined as as the time from the first dose to the first objectively documented disease progression per RECIST v1.1 per Investigator assessment, or death due to any cause in the absence of documented progressive disease (PD). PFS was analyzed using Kaplan-Meier methods. | From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days) | |
Secondary | Overall Survival | Overall survival (OS) was defined as the time from first dose of study drug to death due to any cause. OS was calculated using the Kaplan-Meier method. | From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days) | |
Secondary | The exposure of ABSK021 | The Area Under the Concentration Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Normalized by Dose. | From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days) | |
Secondary | The Maximum Concentration of ABSK021 | Maximum Observed Concentration (Cmax) | From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days) | |
Secondary | The Minimum Concentration of ABSK021 | Minimum Observed Concentration (Cmin) | From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT03662035 -
Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT05085548 -
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04137536 -
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT04617067 -
Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04469556 -
Pancreatic Adenocarcinoma Signature Stratification for Treatment
|
Phase 2 | |
Recruiting |
NCT04104672 -
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT05100329 -
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02101580 -
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06329947 -
A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
|
Phase 2 | |
Recruiting |
NCT02135822 -
Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04803851 -
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03415802 -
Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT05162118 -
Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04643405 -
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03889795 -
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
|
Phase 1 | |
Completed |
NCT01303172 -
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06422156 -
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04931381 -
Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT04482257 -
Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.
|
Phase 1 |